AURKB通过PI3K/AKT信号轴激活EMT,以促进ICC的进展
Peng Ma1, Ying Hao1, Wei Wang1
1Deportment of Hepatobiliary Surgery, Renmin Hospital, Wuhan University, Wuhan, 430060, Hubei Province, People's Republic of China.
Discover oncology
|June 15, 2023
概括
极光激酶B (AURKB) 通过促进细胞增殖和上皮-介质细胞转换 (EMT) 来驱动肝内胆管癌 (ICC) 的进展和转移. 向AURKB可能为ICC提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 肝脏内胆管癌 (ICC) 是一种致命的胆道癌,进展的分子机制尚不清楚.
- 极光激酶B (AURKB) 是细胞分裂的关键调节剂,与各种癌症有关,但其在ICC中的作用尚不清楚.
研究的目的:
- 调查AURKB在肝脏内胆管癌发生和转移中的作用.
- 阐明通过AURKB影响ICC进展的分子途径.
主要方法:
- 在正常胆道组织和具有不同入侵水平的ICC样本中分析AURKB表达.
- 在体外功能增加和丧失实验中,评估AURKB对ICC细胞增殖,迁移和入侵的影响.
- 使用动物模型进行体内研究,以评估AURKB对瘤生长和转移的作用.
- 通过PI3K/AKT信号通路,研究AURKB在表皮层-介质细胞转换 (EMT) 相关基因中的调控作用.
主要成果:
- AURKB的表达逐渐从正常组织增加到高度侵入性的ICC.
- AURKB显著增强了ICC细胞的扩散,迁移和入侵.
- 在活体中,AURKB上调促进了瘤生长和转移.
- 发现AURKB通过PI3K/AKT信号轴调节与EMT相关的基因.
结论:
- 在肝内胆管癌的进展和转移中,AURKB起着至关重要的作用.
- 通过PI3K/AKT通路引发的AURKB激活EMT是ICC进展的关键驱动力.
- AURKB代表了对抗ICC转移和改善患者治疗结果的潜在治疗目标.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:07MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K